Vermillion, Inc. (VRML): Price and Financial Metrics

Vermillion, Inc. (VRML): $4.00

0.33 (-7.62%)

POWR Rating

Component Grades








Add VRML to Watchlist
Sign Up

Industry: Medical - Diagnostics/Research




in industry

VRML Price/Volume Stats

Current price $4.00 52-week high $5.78
Prev. close $4.33 52-week low $0.35
Day low $3.65 Volume 1,319,300
Day high $4.25 Avg. volume 440,144
50-day MA $2.14 Dividend yield N/A
200-day MA $1.07 Market Cap 389.51M

VRML Stock Price Chart Interactive Chart >

VRML Latest News Stream

Event/Time News Detail
Loading, please wait...

VRML Latest Social Stream

Loading social stream, please wait...

View Full VRML Social Stream

Latest VRML News From Around the Web

Below are the latest news stories about Vermillion Inc that investors may wish to consider to help them evaluate VRML as an investment opportunity.

Vermillion changes its name to Aspira Women’s Health Inc.

Vermillion (VRML) has changed its name to Aspira Women’s Health, effective today and will trade on the Nasdaq Stock Market under the new ticker symbol “AWH” and a new CUSIP (04537Y109), effective June 12. Valerie Palmieri, President, and Chief Executive Officer of Aspira Women’s Health said, “Our new company name...

Seeking Alpha | June 11, 2020

Vermillion, Inc. Announces Rebranding and Company Name Change to Aspira Women’s Health Inc.

Vermillion, Inc. (VRML), a bioanalytical-based women’s health company focused on ovarian cancer risk assessment, today announced a major rebranding to reflect the company’s continuing evolution towards becoming a comprehensive gynecologic health company, including a corporate name change to Aspira Women’s Health Inc effective today, June 11, 2020. The company’s common stock will trade on the Nasdaq Stock Market under the new ticker symbol “AWH” effective June 12, 2020.

Yahoo | June 11, 2020

Vermillion set to roll out COVID-19 test and new cancer biomarkers

Vermillion (VRML) subsidiary ASPIRA Labs has finished validating Roche's Elecsys Anti-SARS-CoV-2 antibody blood test in addition to several new oncology biomarkers.The Roche assay demonstrated 100.0% sensitivity and 99.8% specificity.ASPIRA plans to offer the assay and additional pelvic mass risk assessment biomarkers by month-end in conjunction with its proprietary OVA1 plus...

Seeking Alpha | June 10, 2020

Why Vermillion's Stock Is Trading Higher Today

Vermillion, Inc. (NASDAQ: VRML) shares were trading higher on Wednesday, after the company announced it completed validation of new pre-surgical test offerings with OVA1 plus, including coronavirus antibody testings.The company is also expected to join the Russell 3000 Index on June 29.Vermillion is a diagnostic service and bio-analytic solutions provider company. It is engaged in the business of developing and commercializing diagnostic tests for the gynecologic disease. The company's products include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices. Geographically all the operations are functioned from the region of U.S.Vermil...

Yahoo | June 10, 2020

Vermillion Completes Validation of New Pre-Surgical Test Offerings with OVA1®plus, including COVID-19 Antibody Testing and Additional Pelvic Mass Risk Assessment Biomarkers

AUSTIN, Texas, June 10, 2020 -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is excited to announce that its.

Yahoo | June 10, 2020

Read More 'VRML' Stories Here

VRML Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year 304.00%
2023 N/A
2022 N/A
2021 N/A
2020 0.00%
2019 170.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!